Thrombophilic disorders in venous thromboembolism. The clinical perspective;Thrombophile störungen bei venöser thromboembolie aus klinischer perspektive

Medizinische Klinik

Volumn 98, Issue 3, 2003, Pages 133-139

  Schmidt, Benjamin ^b   Schellong, Sebastian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Univ Klin Carl Gustav Carus ^*

Author keywords

Thrombophilia; Treatment duration; Venous thromboembolism

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; HEPARIN COFACTOR II; HOMOCYSTEINE; PLACEBO; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PROTEIN C; PROTEIN S; PROTHROMBIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; DIAGNOSTIC TEST; DYSFIBRINOGENEMIA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LONG TERM CARE; PARTIAL THROMBOPLASTIN TIME; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; TECHNIQUE; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT PLANNING;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; DNA MUTATIONAL ANALYSIS; HEMORRHAGE; HUMANS; RECURRENCE; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0037444779     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-003-1236-2     Document Type: Review

References (35)

1. Kearon C, Crowther M, Hirsh J, Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 2000;51:169-85.
2. Ridker PM. Inherited risk factors for venous thromboembolism: implications for clinical practice. Clin Cornerstone 2000;2:1-14.
3. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jonsson K-A, Hjorth M, Linder O, Boberg J, The Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-5.
4. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA, Johnston M, Douketis J, Roberts R, van Nguyen P, Kassis J, Dolan S, Demers C, Desjardins L, Solymoss S, Trowbridge A. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901-7.
5. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio, A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ascani A, Villalta S, Frulla M, Mosena L, Girolami A, Vaccarino A, Alatri A, Palareti G, Marchesi M, Ambrosio GB, Parisi R, Doria S, Steidl L, Ambrosini F, Silingardi M, Ghirarduzzi A, Iori I, Ageno W, the Warfarin Optimal Duration Italian Trial Investigators. Three months versus one jear of oral anticoagulant therapy for idiopathic deep venous Tthrombosis. N Engl J Med 2001;345:165-9.
6. Hirsh J, Kearon C, Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia [Editorial; Comment]. Arch Intern Med 1997;157:2174-7.
7. Van den Belt AG, Sanson BJ, Simioni P, Prandoni P, Buller HR, Girolami A, Prins MH. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997;157:2227-32.
8. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund S-G, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E, Walter H, Viering S, Hjorth M, Boberg J, The Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-8.
9. Prandoni P, Lensing AW, Bagatella P, Simioni P, Girolami A. Low rate of warfarin-related major bleeding in patients with recurrent venous thromboembolism [Letter]. Thromb Haemost 1999;82:158-9.
10. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-9.
11. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279: 458-62.
12. Prins MH, Hutten BA, Koopman MMW, Büller HR. Long-term treatment of venous thromboembolic disease. Thromb Haemost 1999;82:892-8.
13. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336:399-403.
14. Herrmann FH, Koesling M, Schroder W, Altman R, Jimenez Bonilla R, Lopaciuk S, Perez-Requejo JL, Singh JR. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol 1997;14: 403-11.
15. Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 2001;27: 362-7.
16. Schröder W, Koesling M, Wulff K, Wehnert M, Herrmann FH. Large-scale screening for factor V Leiden mutation in a north-eastern German population. Haemostasis 1996;26:233-6.
17. Stankovics J, Melegh B, Nagy A, Kis A, Molnar J, Losonczy H, Schuler A, Kosztolanyi G. [Incidence of factor V G1681A (Leiden) mutation in samplings from the Hungarian population.] Orv Hetil 1998; 139:1161-3.
18. Eichinger S, Pabinger I, Stumpflen A, Hirschl M, Bialonczyk C, Schneider B, Mannhalter C, Minar E, Lechner K, Kyrle PA. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997;77:624-8.
19. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Leone G. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341: 801-6.
20. Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, Stumpflen A, Schneider B, Lechner K, Kyrle PA. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999;81:14-7.
21. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999;81:684-9.
22. Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996;75:229-32.
23. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
24. Khamashta MA, Williams FM, Hunt BJ. Anticoagulation for venous thromboembolism. N Engl J Med 1999;341:539-40.
25. Bucciarelli P, Rosendaal FR, Tripodi A, Mannucci PM, De Stefano V, Palareti G, Finazzi G, Baudo F, Quintavalla R. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999;19:1026-33.
26. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-9.
27. Barthels M, Depka M von. Das Gerinnungskompendium. Stuttgart: Thieme 2003.
28. Müller-Berghaus G, Pötzsch B. Hämostaseologie. Berlin-Heidelberg: Springer 1999.
29. Simmonds RE, Ireland H, Lane DA, Zoller B, Garcia de Frutos P, Dahlback B. Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med 1998; 128:8-14.
30. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S. High plasma levels of factor VIII and the risk of recurrent venous Tthromboembolism. N Engl J Med 2000;343:457-62.
31. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000;342:696-701.
32. Den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
33. Sanson BJ, Simioni P, Tormene D, Moia M, Friederich PW, Huisman MV, Prandoni P, Bura A, Rejto L, Wells P, Mannucci PM, Girolami A, Buller HR, Prins MH. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999;94:3702-6.
34. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-31.
35. Deutsche Gesellschaft für Angiologie. Leitlinien zur Diagnostik und Therapie der Venenthrombose und Lungenembolie. Vasa 2002;31:3-19.